大剂量阿托伐他汀对老年急性心肌梗死患者造影剂肾病的预防和安全性研究被引量：9

下载PDF

导出

摘要目的观察大剂量阿托伐他汀对老年PCI造影剂肾病患者的预防和安全性.方法选取201 7年1~12月南京市大厂医院心血管内科住院的老年急性心肌梗死行PCI患者90例,随机分为观察组45例和对照组45例.在PCI术前4d及术后3d,2组给予常规水化治疗、大量饮水、利尿等.在此基础上对照组口服阿托伐他汀10 mg/晚,观察组40 mg/晚.观察2组术前和术后血清肌酐、尿素和胱抑素C水平变化,记录2组治疗过程中造影剂肾病及不良反应发生情况.结果 2组术前血清肌酐、尿素和胱抑素C水平比较,差异无统计学意义(P>0.05).2组术后血清肌酐、尿素和胱抑素C水平较术前明显升高,差异有统计学意义(P<0.05).观察组术后血清肌酐、尿素和胱抑素C水平较对照组明显降低,差异有统计学意义(P<0.05).观察组造影剂肾病发生率明显低于对照组,差异有统计学意义(8.9% vs 26.7%,P<0.05).2组不良反应发生率比较,差异无统计学意义(P>0.05).结论服用大剂量阿托伐他汀可明显改善老年心肌梗死患者PCI术后的肾功能,减少造影剂肾病的发生,是一种防治PCI造影剂肾病较好的方式.

作者张启杰焦慧杨宏飞邵良发汪丽丽

机构地区东南大学附属中大医院江北院区南京市大厂医院心血管内科东南大学附属中大医院江北院区南京市大厂医院神经内科东南大学附属中大医院江北院区南京市大厂医院肾内科

出处《中华老年心脑血管病杂志》 CAS 北大核心 2019年第7期759-761,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

关键词心肌梗死造影剂肾病降血脂药物饮水

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1杨建昌,熊宗华,鲁玉明,唐艳,周文汀.不同剂量瑞舒伐他汀对冠脉造影术后造影剂肾病的影响[J].贵州医药,2014,38(11):1020-1022. 被引量：5
2黄帆,陈波.造影剂肾病发病机制及治疗的研究进展[J].医学综述,2017,23(14):2814-2818. 被引量：19

二级参考文献12

1Roh JW,Kim BK,Lee CH,et al. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women [ J]. Oncol Res, 2010,18(9) :453.
2Jabara R, Gadesam RR, Pendyala LK, et al. Impact of the definition utilized on the rate of contrastqnduced nephropathy in percutaneous coronary intervention [J]. Am J Cardiol,2009,103(12) :1657-1662.
3Bartorelli AL,Marenzi G. Con trast-induced Nephropa- thy[J]. J Interv Cardiol, 2008,21 ( 1 ): 74-85.
4Persson PB, Hansell P, Liss P. Pathophysiology of con- trast medium-induced nephropathy [J]. Kidney Int, 2005,68(1) : 14-22.
5Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after per- cutaneous coronary intervention[J]. Cir culation, 2002, 105(19) :2259-2264.
6Bashore TM, Bates ER, Berger PB, et al. Catheteriza- tion laboratory stand ards: a report of the American College of Cardiology task force on clinical expert con- sensus documents[J]. JACC, 2001,37 : 2170-2174.
7Nusca A, Melfi R, Patti G, et al. Statin loading before percutaneous coronary intervention: proposed mecha- nisms and applications [J]. Future Cardiol, 2010,6 ( 5 ): 579-589.
8Mussep M,Dalla VM, Fioretto P, et al. CystainC is a more sensitive marker chan creatinine for che estima- tion of GFR in type 2 diabetic patients[J]. Kidney Int, 2002,61 (4) : 1453-1461.
9Ye M,Grant M,Sharma M,et al. Cyst fluid from hu- man autosnmal dominant polycystic kidneys promotes cyst forfation and expansion by renal epithelial cells in vitro[J]. J Am Soc Nephrol, 1992,3 (2) : 984-994.
10Patti G,Nusea A,Chello M,et al. Usefulness of statin preetreatment to prevett contrast-induced nephropa- thy and to improve long-term outcome in patients un- dergoing pereutaneous coronary intervention [J]. Am J Cardiol, 2008,101 (3) : 279-285.